Gamma Therapeutics, Inc.

Gamma Therapeutics, developing solutions for combat casualty care, announced the company has been awarded a U.S Provisional Patent for the GammaMist Blood Clotting Bypass Device designed to address hemorrhage problems during warfighter medevac.

Gamma Therapeutics, an Oregon biotech venture developing solutions for cardiovascular disease risk assessment, announced today Dr. David Farrell, CSO will present his research of a novel CVD risk assay, branded GammaCoeur,™ at the Oak Ridge Conf.

Gamma Therapeutics, a biotech venture developing cardiac biomarkers, signed a mfg contract with ZEUS Scientific, one of the world’s leading mfgs. of autoimmune & infectious disease immunoassay kits & products for the clinical diagnostic industry.

Gamma Therapeutics, developing cardiovascular disease risk assays, surgical therapy and military medicine solutions, was named as a Finalist in the Annual Tom Holce Entrepreneurship Awards

Dr. David H. Farrell, GT’s Founder and CSO will present scientific data related to his three decades of research in human blood fibrinogen, hemostasis and thrombosis at the American Heart Association Conf. in Chicago, IL, April 28-30, 2011.

Gamma Therapeutics, an Oregon biotech venture announced its been awarded a Phase II SBIR grant from the NIH to commercialize its GammaCoeur CVD Risk Assay. The $1.1 M grant allows GT to complete development, testing & final FDA approval by 2012.

Health Diagnostic Laboratory, Richmond, VA & Gamma Therapeutics,Portland, OR, biotech venture start-ups, are collaborating on the development of a novel cardiovascular disease diagnostic assay to assess CVD patient risk of heart attack or stroke.

February 1, 2011--Portland, Oregon-Gamma Therapeutics, Inc., an Oregon-based biotech venture developing diagnostic test solutions for the cardiovascular disease industry, announced today the appointment of its new Board of Science Advisors.